TNF-α/IL-1/NF-κB transduction pathway in human cancer prostate

Histology and Histopathology

Volumn 23, Issue 10, 2008, Pages 1279-1290

  Royuela, Mar ^a   Rodríguez Berriguete, Gonzalo ^a   Fraile, Benito ^a   Paniagua, Ricardo ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

IL 1; NF B; NIK; P38; Prostate carcinoma; TNF

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; APOPTOSIS SIGNAL REGULATING KINASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROTEIN BCL 2; PROTEIN P21; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR ELK 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; ANTINEOPLASTIC AGENT; NF KAPPA B KINASE; NF-KAPPA B KINASE; PROTEIN SERINE THREONINE KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; NONHUMAN; PROGNOSIS; PROSTATE CANCER; PROSTATE CARCINOMA; REVIEW; SIGNAL TRANSDUCTION; TRANSURETHRAL RESECTION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; INTERLEUKIN-1; MALE; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54449093753     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Aaltomaa S., Lipponen P., Eskelinen M., Ala-Opas M. and Kosma V.M. (1999). Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer. Prostate 39, 8-15.
2. Abdul M. and Hoosein N. (2002). Relationship of the interleukin-1 system sith neuroendocrine and exocrine markers in human colon cancer cells lines. Cytokine 18, 86-91.
3. Andreakos E., Williams R.O., Wales J., Foxwell B.M., Feldmann M. (2006). Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc. Natl. Acad. Sci. USA 103, 14459-14464.
4. Arend W.P. (2002). The balance between IL-1 and IL-1Rα in disease. Cytokine Growth Factor Rev. 13, 323-340.
5. Balkwill F. (2002). Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev. 13, 135-141.
6. Bazzoni F. and Beutler B. (1996). The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 385, 733-736.
7. Ben-Levy R., Hooper S., Wilson R., Peterso H.F. and Marshall C.J. (1998). Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP Kinase-2. Curr. Biol. 8, 1049-1057.
8. Bertazza L. and Mocellin S. (2008). Tumor necrosis factor (TNF) biology and cell death. Front. Biosci. 13, 2736-2743.
9. Boraschi D., Bossu P., Macchia G., Ruggiero P. and Tagliabue A. (1996). Structure-function relationship in the IL-1 family. Front. Biosci. 1, 270-308.
10. Cao Z., Henzel W.J. and Gao X. (1996). IRAK: a kinase associated with the interleukin-1 receptor. Science 271, 1128-1131.
11. Cano E. and Mahadevan C. (1995). Parallel signal processing among mammalian MAP kinases. Trends Biochem. Sci. 20, 117-122.
12. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N. and Williamson B. (1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666-3670.
13. Chang J. and Girgis L. (2007). Clinical use of anti-TNF-alpha biological agents - a guide for GPs. Aust. Fam. Physician 36, 1035-1038.
14. Chen C.D. and Sawyers C.L. (2002). NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol. Cell. Biol. 22, 2862-2870.
15. Chen J., Sadowski H.B., Kohanski R.A. and Wang L.H. (1997). Stat 5 is a physiological activator of the insulin receptor. Proc. Natl. Acad. Sci. USA 94, 2295-2300.
16. Coxon A., Bolon B., Estrada J., Kaufman S., Scully S., Rattan A., Duryea D., Hu Y., Rex K., Pacheco E., Van G., Zack D. and Feige U. (2002). Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjunvant arthritis. Arthritis Rheum. 46, 2604-2612.
17. Dejardin E., Deregowski V., Chapelier M., Jacobs N., Gielen J., Merville M. and Bours V. (1999). Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene 18, 2567-2577.
18. De Miguel M.P., Royuela M., Bethencourt F.R., Santamaría L., Fraile B. and Paniagua R. (2000). Immuno-expression of tumour necrosis factor-α and its receptors 1 and 2 correlates with proliferation/ apoptosis equilibrium in normal, hyperplasic and carcinomatous human prostate. Cytokine 5, 535-538.
19. DiDonato J.A., Hayakawa M., Rothwarf D.M., Zandi E. and Karin M. (1997). A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388, 548-554.
20. Dinarello C.A. (1998). Interleukin-1, interleukin-1 receptors and interleukin 1 receptor antagonist. Int. Rev. Immunol. 16, 457-499.
21. Domingo-Domenech J., Mellado B., Ferrer B., Truan D., Codony-Servat J., Sauleda S., Alcover J., Campo E., Gascon P., Rovira A., Ross J.S., Fernandez P.L. and Albanell J. (2005). Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br. J. Cancer 93, 1285-1294.
22. Foa R., Massaia M., Cardona S., Tos A.G., Bianchi A., Attisano C., Guarini A., di Celle P.F. and Fierro M.T. (1990). Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 76, 393-400.
23. Garcia-Tuñon I., Ricote M., Ruiz A., Fraile B., Paniagua R. and Royuela M. (2006). Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci. 97, 1044-1049.
24. Gasparian A.V., Yao Y.J., Kowalczyk D., Lyakh L.A., Karseladze A., Slaga T.J. and Budunova I.V. (2002). The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J. Cell Sci. 115, 141-151.
25. Giri D. and Ittmann M. (2000). Interleukin-1α is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. Am. J. Pathol. 157, 249-255.
26. Grenfell S., Smithers N., Witham S., Shaw A., Graber P. and Solari R. (1991). Analysis of mutations in the putative nuclear localization sequence of interleukin-1 beta. Biochem. J. 280, 111-116.
27. Hacham M., Argov S., White R.M., Segal S. and Apte R.N. (2002). Different patterns of interleukin-1alpha and interleukin-1beta expression in organs of normal young and old mice. Eur. Cytokine Netw. 13, 55-65.
28. Hoosein N.M. (1998). Neuroendocrine and immune mediators in prostate cancer progression. Front Biosci. 3, D1274-1279.
29. Hubel K., Mansmann G., Schafer H., Oberhauser F., Diehl V. and Engert A. (2000). Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF. Cytokine 12, 1797-1800.
30. Ichijo H., Nishida E., Irie K., Ten Kijke P., Saitoh M. and Moriguchi T. (1996). Induction of apoptosis by ASK-1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275, 90-94.
31. Irie A., Lee K.E., Kadowaki K., Toda K. and Yamada Y. (1999). Elevation of serum and urine tumor necrosis factor levels after transurethral resection of the prostate. Nippon Hinyokika Gakkai Zasshi. 90, 502-508.
32. Juric D.M. and Carman-Krzan M. (2001). Interleukin-1β, but not IL-1α, mediates nerve growth factor secretion from rat astrocytes via type I IL-1 receptor. Int. J. Dev. Neurosci. 19, 675-683.
33. Kim H.L., Vander D.J., Yang X., Benson D.A., Dubauskas Z. and Yoshida B.A. (2001). Mitogen-Activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res. 61, 2833-2837.
34. Kollias G., Douni E., Kassiotis G. and Kontoyiannis D. (1999). On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol. Rev. 169, 175-194.
35. La E., Rundhaug J.E., Pavone A. and Fisher S.M. (2002). Regulation of trans-cription of the intracellular interleukin-1 receptor antagonist gene AP-1 in mouse carcinoma cells. Mol. Carcinog. 33, 237-243.
36. Labriola-Tompkins E., Chandran C., Kaffka K.L., Biondi D., Graves B.J., Hatada M., Madison V.S., Karas J., Kilian P.L. and Ju G. (1991). Identification of the discontinuous binding site in human interleukin 1b for the type I interleukin 1 receptor. Proc. Natl. Acad. Sci. USA 88, 11182-11186.
37. Lázár-Molnár E., Hegyesi H., Tóth S. and Falus A. (2000). Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12, 547-554.
38. Lessard L., Karakiewicz P.I., Bellon-Gagnon P., Alam-Fahmy M., Ismail H.A., Mes-Masson A.M. and Saad F. (2006). Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin. Cancer Res. 12, 5741-5745.
39. Lewis A.M., Varghese S., Xu H. and Alexander H.R. (2006). Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J. Transl. Med. 4, 48.
40. Li S.P., Meng S.Y. and Li R. (2006). Clinical evaluation of four cytokines in serum and prostatic fluid in chronic abacterial prostatitis. Zhonghua Nan Ke Xue. 12, 25-27.
41. Lowenthal J. and MacDonald H.R. (1986). Binding and internalisation of interleukin 1 by T cells. J. Exp. Med. 164, 1060-1074.
42. Lüschen S., Scherer A., Ussat S., Ungenfroren H. and Adam-Klages S. (2004). Inhibition of p38 mitogen-activated protein kinase reduces TNF induced activation of NF-κB, elicits caspase activity, and enhances cytotoxicity. Exp. Cell. Res. 293, 196-206.
43. Matanic D., Beg-Zec Z., Stojanovic D., Matakoric N., Flego V. and Milevoj-Ribic F. (2003). Cytokines in patients with lung cancer. Scand. J. Immunol. 57, 173-178.
44. Michalaki V., Syrigos K., Charles P. and Waxman J. (2004). Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer 90, 2312-2316.
45. Mocellin S. and Nitti D. (2008). TNF and cancer: the two sides of the coin. Front. Biosci. 13, 2774-2783.
46. Muenchen H.J., Lin D.L., Walsh M.A., Keller E.T. and Pienta K.J. (2000). Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor". Clin. Cancer Res. 6, 1969-1977.
47. Nuñez C., Cansino J.R., Bethencourt F., Pérez-Utrilla M., Fraile B., Martínez-Onsurbe P, Paniagua R and Royuela M. (2008). TNF/IL-1/NIK/NF-κB transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma). Histopathology (in press).
48. Perambakam S.M., Srivastava R. and Peace D.J. (2005). Distinct cytokine patterns exist in peripheral blood mononuclear cell cultures of patients with prostate cancer. Clin. Immunol. 117, 94-99.
49. Pfitzenmaier J., Vessella R., Higano C.S., Noteboom J.L., Wallace D. Jr and Corey E. (2003). Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97, 1211-1216.
50. Pilati P., Rossi C.R. and Mocellin S. (2008). Strategies to enhance the anticancer potential of TNF. Front. Biosci. 13, 3181-3193.
51. Polascik T.J., Oesterling J.E. and Partin A.W. (1999). Prostate specific antigen: a decade of discovery - what we have learned and where we are going?. J. Urol. 162, 293-306.
52. Rao V.N. and Reddy E.S. (1994). Elk-1 proteins interact with MAP kinases. Oncogene 9, 1855-1582.
53. Raingeaud J., Whitmarsh A.J., Barrett T., Derijard B. and Davis R.J. (1996). MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell. Biol. 16, 1247-1255.
54. Razumov S.V., Medvedev A.A., Chirun N.V., Sivkov A.V., Oshchepkov V.N. and Siniukhin V.N. (2003). Role of cytokines in the diagnosis of chronic prostatitis. Urologia 6, 25-28.
55. Ricote M., Royuela M., Garcia-Tuñon I., Bethencourt F.R., Paniagua R. and Fraile B. (2003). Pro-apoptotic tumor necrosis factor-alpha transduction pathway in normal prostate, benign prostatic hyperplasia and prostatic carcinoma. J. Urol. 170, 787-790.
56. Ricote M., Garcia-Tuñon I., Bethencourt F.R., Fraile B., Paniagua R. and Royuela M. (2004). Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 100, 1388-1396.
57. Ricote M., Garcia-Tunon I., Bethencourt F., Fraile B., Onsurbe P., Paniagua R. and Royuela M. (2006). The p38 transduction pathway in prostatic neoplasia. J. Pathol. 208, 401-407.
58. Rosati O. and Martin M.U. (2002). Identification and characterization of murine IRAK-2. Biochem. Biophys. Res. Commun. 297, 52-58.
59. Roscigno M., Scattoni V., Bertini R., Pasta A., Montorsi F. and Rigatti P. (2004). Diagnosis of prostate cancer. State of the art. Minerva Urol. Nefrol. 56, 123-145.
60. Ross J.S., Kallakury B.V., Sheehan C.E., Fisher H.A., Kaufman R.P., Kaur P., Gray K. and Stringer B. (2004). Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin. Cancer Res. 10, 2466-2472.
61. Royuela M., De Miguel M.P., Bethencourt F., Fraile B., Arenas M.I. and Paniagua R. (2000). IL-2, Its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. Growth Factors 18, 135-146.
62. Royuela M., Arenas M.I., Bethencourt F.R., Sanchez-Chapado M., Fraile B. and Paniagua R. (2001). Immuno expressions of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates. Eur. Cytokine Netw. 12, 654-663.
63. Royuela M., Arenas M.I., Bethencourt F.R., Sánchez-Chapado M., Fraile B. and Paniagua R. (2002). Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic and carcinomatous human prostate. Hum. Pathol. 33, 299-306.
64. Royuela M., Ricote M., Parsons M.S., García-Tuñón I., Paniagua R. and de Miguel M.P. (2004). Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic and malignant human prostate. J. Pathol. 202, 41-49.
65. Rzymski P., Opala T., Wilczak M., Wozniak J. and Sajdak S. (2005). Serum tumor necrosis factor alpha receptors p55/p75 ratio and ovarian cancer detection. Int. J. Gynaecol. Obstet. 88, 292-298.
66. Shariat S.F., Andrews B., Kattan M.W., Kim J., Wheeler T.M. and Slawin K.M. (2001). Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58, 1008-1015.
67. Shukla S., MacLennan G.T., Fu P., Patel J., Marengo S.R., Resnick M.I. and Gupta S. (2004). Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 6, 390-400.
68. Singer C.F., Hudelist G., Gschwantler-Kaulich D., Fink-Retter A., Mueller R., Walter I., Czerwenka K. and Kubista E. (2006). Interleukin-1alpha protein secretion in breast cancer is associated with poor differentiation and estrogen receptor alpha negativity. Int. J. Gynecol. Cancer 16, 556-559.
69. Sovak M.A., Bellas R.E., Kim D.W., Zanieski G.J., Rogers A.E., Traish A.M. and Sonenshein G.E. (1997). Aberrant nuclear factorkappaB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100, 2952-2960.
70. Suh J. and Rabson A.B. (2004). NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J. Cell. Biochem. 91, 100-117.
71. Sun J., Wiklund F., Hsu F.C., Balter K., Zheng S.L., Johansson J.E., Chang B., Liu W., Li T., Turner A.R., Li L., Li G., Adami H.O., Isaacs W.B., Xu J. and Gronberg H. (2006). Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 15, 480-485.
72. Stamey T.A. (2001). Preoperative serum prostate-specific antigen (PSA) below 10 microg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. Clin. Chem. 47, 631-634.
73. Stehlik C., de Martin R., Binder B.R. and Lipp J. (1998). Cytokine induced expression of porcine inhibitor of apoptosis protein (IAP) family member is regulated by NF-kappa B. Biochem. Biophys. Res. Commun. 243, 827-832.
74. Szlosarek P.W. and Balkwill F.R. (2003). Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Oncology 4, 565-573.
75. Tamatani M., Che Y.H., Matsuzaki H., Ogawa S., Okado H. and Miyake S. (1999). Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFκB activation in primary hippo-campal neurons. J. Biol. Chem. 274, 8531-8538.
76. Tartaglia L.A., Ayres T.M., Wong G.H. and Goeddel D.V. (1993). A novel domain within the 55 kDa TNF receptor signals cell death. Cell 74, 845-853.
77. Twillie D.A., Eisenberger M.A., Carducci M.A., Hseih W.S., Kim W.Y. and Simons J.W. (1995). Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45, 542-549.
78. Wajant H. and Scheurich P. (2001). Necrosis factor receptor-associated factor (TRAF-2) and its role in TNF signaling. Int. J. Biochem. Cell. Biol. 33, 19-32.
79. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V. and Baldwin A.S. Jr (1998). NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680-1683.
80. Wang W., Abbruzzese J.L., Evans D.B., Larry L., Cleary K.R. and Chiao P.J. (1999). The nuclear factor-IB transcription factor is constitutively active in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 5, 119-127.
81. Wiedenmann B., Reichardt P., Räth U., Theilmann L., Schüle B., Ho A.D., Schlick E., Kempeni J., Hunstein W. and Kommerell B. (1989). Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. J. Cancer Res. Clin. Oncol. 115, 189-192.
82. Wise G.J., Marella V.K., Talluri G. and Shirazian D. (2000). Cytokine variations in patients with hormone treated prostate cancer. J. Urol. 164, 722-725.
83. Wu J.T. and Kral J.G. (2005). The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J. Surg. Res. 23, 158-169.
84. Xiao D., Qu X. and Weber H.G. (2002). GRP receptor-mediated immediate early gene expresión and transcription factor Elk-1 activation in prostate cancer cells. Regul. Peptides 109, 141-148.
85. Zhang G. (2004). Tumor necrosis factor family ligand-receptor binding. Curr. Opin. Struct. Biol. 14, 54-60.
86. Zheng C.F. and Guan K.L. (1994). Cytoplasmic localization of the mitogen-activated protein kinase activator MEK. J. Biol. Chem. 269, 19947-19952.
87. Zubelewicz B., Muc-Wierzgof M., Wierzgof J., Romanowski W., Mazurek U., Wilczok T. and Podwinska E. (2002). Genetic disregulation of gene coding tumor necrosis factor alpha receptors (TNF alpha Rs) in follicular thyroid cancer-preliminary report. J. Biol. Regul. Homeost. Agents 16, 98-104.